The ZAMASA Foundation is a research foundation focused specifically on leading edge research into multiple myeloma, with an emphasis on recent genetically engineered advances in immunotherapy. The Foundation will also focus on the advancement of genetic approaches to treatments that are focused on some of the more debilitating aspects associated with disease progression (such as bone and kidney damage). Initiatives targeting more effective early screening of multiple myeloma may also be considered. Through collaboration and direct funding the ZAMASA Foundation will contribute to ongoing global efforts to provide patients with longevity and enhanced quality of life. The ZAMASA Foundation will look to advance immunotherapy research as it applies to multiple myeloma through a variety of means, including: - Direct research - Co-supporting with other charitable organisations - Major projects - Clinical Trials Through the continued rapid advancement of immunotherapies the ZAMASA Foundation envisions a world where multiple myeloma is either curable or manageable as a long term chronic condition. The ZAMASA Foundation is currently in discussions with St Vincent’s Centre for Applied Medical Research (AMR) in relation to advancing research and training in Multiple Myeloma. Each year in Australia around 1,800 people are diagnosed with multiple myeloma. Although treatment advances have progressed improving survival outcomes, most patients eventually relapse and develop resistance to their treatments. Depending on prognostic factors, multiple myeloma has a median survival rate of 4-7 years, with a five-year relative survival rate at around 50% and with a 10-year survival rate of approximately 27%. Multiple myeloma is an incurable B-cell malignancy characterised by the aberrant expansion of clonal malignant plasma cells into bone marrow. The cancerous cells are called myeloma cells. Multiple Myeloma is one of the three most common blood cancers.